This study found that recombinant human type XVII collagen (rhCOL17A1) promotes hair growth by activating the Wnt/β-catenin and SHH/GLI signaling pathways and increasing type XVII collagen expression, with significant effects observed in both cell and mouse models.
May 2025 in “Acta Biomaterialia” This study developed microneedles combining insulin-like growth factor-1 and type XVII collagen, showing more effective hair regeneration and reduced inflammation compared to minoxidil in a mouse model of androgenetic alopecia.
January 2025 in “Regenerative Biomaterials” This study found that a microneedle patch with recombinant collagen XVII significantly improved hair coverage, follicle density, and angiogenesis in an androgenic alopecia mouse model, showing potential as a novel therapeutic strategy alongside established treatments like minoxidil.
September 2024 in “Journal of Medicine and Life” In this study, researchers identified a recurrent nonsense mutation, c.409C>T (p.Arg137*), in the COL7A1 gene through whole exome sequencing in a family with autosomal recessive dystrophic epidermolysis bullosa, demonstrating the importance of this method for diagnosing genetically complex conditions.
September 2016 in “Journal of dermatological science” This study found that COL17 plays a key role in regulating epidermal keratinocyte differentiation and proliferation, influencing the expression of differentiation markers and cellular growth in specific conditions.